Efficacy and Safety of Lanreotide Autogel (ATG) in Combination With Temozolomide in Subjects With Thoracic Neuroendocrine Tumors.
- 20 November 2024 - 1 mins read
The purpose of the protocol is to evaluate the efficacy and safety of Lanreotide ATG 120 mg in combination with Temozolomide in subjects with unresectable advanced neuroendocrine tumours of the lung or thymus as Disease Control Rate at 9 months.
20 November 2024
1 mins read
Which is the Best Dose of Dysport in Helping With Hip Pain for Children With Cerebral Palsy?
20 November 2024
1 mins read
Study to Assess Impact of Dysport Injections Early After Stroke on Upper Limb Spasticity Progression
20 November 2024
1 mins read
Efficacy and Safety Study of Botulinum Toxin Type-A (Dysport®) in Continent Female Subjects Suffering From Idiopathic Overactive Bladder
20 November 2024
1 mins read
Dysport® Pediatric Lower Limb Spasticity Follow-on Study
20 November 2024
1 mins read
Dysport® Adult Lower Limb Spasticity Follow-on Study
20 November 2024
1 mins read
Dysport® Pediatric Lower Limb Spasticity Study
20 November 2024
1 mins read
Dysport® Adult Lower Limb Spasticity Study
20 November 2024
1 mins read
Efficacy and Safety of Botulinum Toxin Type A Haemagglutinin Complex Next Generation (BTX-A-HAC NG) in Glabellar Lines
20 November 2024
1 mins read
Efficacy and Safety of Clostridium Botulinum Toxin Type A to Improve Appearance of Moderate to Severe Glabellar Lines
20 November 2024
1 mins read